Seqirus Revenue and Competitors

Summit, NJ USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Seqirus's estimated annual revenue is currently $849.8M per year.(i)
  • Seqirus's estimated revenue per employee is $201,000

Employee Data

  • Seqirus has 4228 Employees.(i)
  • Seqirus grew their employee count by 2% last year.

Seqirus's People

NameTitleEmail/Phone
1
VP Commercial Operations, Asia PacificReveal Email/Phone
2
Head, Warehousing & Transport (RP)Reveal Email/Phone
3
VP Interim Head Global Operations Reveal Email/Phone
4
VP HRReveal Email/Phone
5
SVP, Strategy & Innovation Reveal Email/Phone
6
Head Tax, Seqirus; Head Tax, EMEA, CSL BehringReveal Email/Phone
7
Head Quality ControlReveal Email/Phone
8
VP, General CounselReveal Email/Phone
9
Director EngineeringReveal Email/Phone
10
Director Quality ControlReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Seqirus?

Seqirus, part of the CSL Group, is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, the two businesses joined forces to create Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 2,000 employees, significant manufacturing capacity and a commercial presence in over 20 countries. In Australia and New Zealand, Seqirus markets a comprehensive range of vaccines and speciality pharmaceutical products. It also manufactures products of national significance for Australia, including antivenoms and Q fever vaccine, and supplies diagnostic reagents in the Australasia region. Seqirus cold-chain logistics business ensures the integrity of CSL products, as well as those of our customers, as they are safely delivered across Australia. Vaccines, Antivenoms, Contract logistics, In-licensing, Immunohaematology, Pharmaceuticals

keywords:N/A

N/A

Total Funding

4228

Number of Employees

$849.8M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Seqirus News

2022-04-17 - Viral Vaccines Market Size And Forecast | Sanofi Pasteur ...

Sanofi Pasteur, Seqirus A CSL, GlaxoSmithKline plc. Novartis Merck & Co., Inc. MedImmune, LLC, Emergent Product Development Gaithersburg...

2022-04-06 - H5N1 Vaccine Readied for a Possible Influenza Pandemic

... H5N1 subunit influenza virus developed by Seqirus Inc, Holly Springs, ... therapeutic area head, pandemic and other vaccines, Seqirus,...

2022-03-22 - Seqirus Receives Health Canada Approval for Expanded Age ...

MONTREAL, March 28, 2022 /CNW/ -- Seqirus, a global leader in influenza prevention, announced today that it has received Health Canada...